Vnitr Lek 2025, 71(8):490-496

Pancreatic cancer and diabetes mellitus

Jan Křivinka1, Petr Dítě2, Beatrice Mohelníková Duchoňová3, Ondřej Urban1, Lumír Kunovský1, 4, 5
1 II. interní klinika - gastroenterologická a geriatrická FNOL; Lékařská fakulta Univerzity Palackého v Olomouci
2 Interní gastroenterologická klinika FN Brno a LF MU Brno
3 Onkologická klinika FNOL; Lékařská fakulta Univerzity Palackého v Olomouci
4 Gastroenterologické oddělení a digestivní endoskopie, LF MU a Masarykův onkologický ústav, Brno
5 Chirurgická klinika LF MU a FN Brno

Pancreatic cancer (PC) is one of the most lethal malignancies with increasing incidence. Diabetes mellitus (DM) is a common condition that shares multiple pathophysiological links with pancreatic cancer. New-onset diabetes may represent an early manifestation of pancreatic cancer, whereas long-standing diabetes slightly increases its risk. Recognizing features of paraneoplastic diabetes is essential in clinical practice. This article reviews current knowledge on the PC-DM relationship, emphasizing diagnostic and therapeutic implications.

Keywords: pancreatic cancer, diabetes mellitus, paraneoplastic syndrome, early diagnosis, surveillance.

Accepted: November 26, 2025; Published: December 15, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Křivinka J, Dítě P, Mohelníková Duchoňová B, Urban O, Kunovský L. Pancreatic cancer and diabetes mellitus. Vnitr Lek. 2025;71(8):490-496.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ferlay J, Ervik M, Lam F. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. 2024.
    2. Karty diagnóz C25. [Internet]. Svod.cz; [cited 20251118]. Available from: https://www.svod.cz/res/file/kartydiagnoz/c25.pdf.
    3. Vaněk P, Eid M, Psar R, et al. Current trends in the diagnosis of pancreatic cancer. Vnitřní lékařství. 2022;68(6):363370. Go to original source...
    4. Benešová K, Jarkovský J, Klika P, et al. Epidemiologie diabetes mellitus. Národní zdravotnický informační portál [Internet]. Praha: Ministerstvo zdravotnictví ČR a Ústav zdravotnických informací a statistiky ČR; 2023 [cited 20251118]. Available from: http://www.nzip.cz/data/1768diabetesmellitusotevrenadata?utm_source=chatgpt.com.
    5. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):1249. Go to original source...
    6. Fan M, Deng G, Ma Y, et al. Survival outcome of different treatment sequences in patients with locally advanced and metastatic pancreatic cancer. BMC Cancer [Internet]. 2024;24(1):???. (ISSN 14712407). doi:10.1186/s12885024118238. Go to original source...
    7. Picozzi VJ, Oh SY, Edwards A, et al. FiveYear Actual Overall Survival in Resected Pancreatic Cancer: A Contemporary SingleInstitution Experience from a Multidisciplinary Perspective. Ann Surg Oncol. 2017;24(6):17221730. Go to original source...
    8. Li X, Chen Y, Qiao G, et al. 5Year survival rate over 20 % in pancreatic ductal adenocarcinoma: A retrospective study from a Chinese highvolume center. Cancer Lett. [Internet]. 2025;619:217658. (ISSN 03043835). doi:10.1016/j.canlet.2025.217658. Go to original source... Go to PubMed...
    9. Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med. 2014;371(11):10391049. Go to original source...
    10. Moore SF, Price S, Konya J, et al. Risk factors for pancreatic cancer in electronic health records: an umbrella review of systematic reviews and metaanalyses. EClinicalMedicine [Internet]. 2025;85:103297. (ISSN 25895370). doi:10.1016/j.eclinm.2025.103297. Go to original source... Go to PubMed...
    11. Iodice S, Gandini S, Maisonneuve P. Tobacco and the risk of pancreatic cancer: a review and metaanalysis. Langenbeck's Arch Surg. 2008;393(4):535545. Go to original source...
    12. Trna J, Kala Z, Kunovský L. Klinická pankreatologie. 2. přeprac. a dopl. vyd. Praha: Maxdorf; 2021. ISBN 9788073456979.
    13. Klein AP. Genetic susceptibility to pancreatic cancer. Mol Carcinog. 2011;51(1):1424. Go to original source...
    14. Vaněk P, Andrašina T, Bitnerová V, et al. Pancreatic cancer surveillance in highrisk individuals: Position statement of professional societies. Gastroenterologie a hepatologie [Internet]. 2023;77(6):529538. (ISSN 18047874). doi:10.48095/ccgh2023529. Go to original source...
    15. Naudin S, Wang M, Dimou N, et al. Alcohol intake and pancreatic cancer risk: An analysis from 30 prospective studies across Asia, Australia, Europe, and North America. PLOS Med [Internet]. 2025;22(5):e1004590. (ISSN 15491676). doi:10.1371/journal.pmed.1004590. Go to original source... Go to PubMed...
    16. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care [Internet]. 2011;35(Suppl_1):S64S71. (ISSN 01495992). doi:10.2337/dc12s064. Go to original source...
    17. Leroith D, Scheinman E, BittonWorms K. The role for insulin and insulinlike growth factors in the increased risk of cancer in diabetes. Rambam Maimonides Med J [Internet]. 2011;2(2):e0043. (ISSN 20769172). doi:10.5041/rmmj.10043. Go to original source... Go to PubMed...
    18. Duan X, Wang W, Pan Q, Guo L. Type 2 diabetes mellitus intersects with pancreatic cancer diagnosis and development. Front Oncol [Internet]. 2021;11:730038. (ISSN 2234943X). doi:10.3389/fonc.2021.730038. Go to original source... Go to PubMed...
    19. Huxley R, AnsaryMoghaddam A, Berrington de González A, et al. TypeII diabetes and pancreatic cancer: a metaanalysis of 36 studies. Br J Cancer [Internet]. 2005;92(11):20762083. (ISSN 00070920). doi:10.1038/sj.bjc.6602619. Go to original source... Go to PubMed...
    20. Fu YB, Yang G, Qiu JD. Diabetes mellitus and early detection of pancreatic cancer. Cancer Screen Prev [Internet]. 2022;1(1):6471. (ISSN 28353315). doi:10.14218/csp.2022.00013. Go to original source...
    21. Gullo L, Pezzilli R, MorselliLabate AM. Diabetes and the risk of pancreatic cancer. N Engl J Med [Internet]. 1994;331(2):8184. (ISSN 00284793). doi:10.1056/nejm199407143310203. Go to original source... Go to PubMed...
    22. Trna J, Dítě P, Hermanová M, Adamcová A. Výskyt diabetes mellitus u pacientů s karcinomem slinivky břišní. Gastroenterologie a hepatologie. 2008;62(2):69-73.
    23. Pannala R, Leirness JB, Bamlet WR, et al. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology [Internet]. 2008;134(4):981987. (ISSN 00165085). doi:10.1053/j.gastro.2008. 01. 039. Go to original source...
    24. Duggan SN, O'Connor DB, Antanaitis A, et al. Metabolic dysfunction and diabetes mellitus during longterm followup of severe acute pancreatitis: a casematched study. Pancreatology [Internet]. 2020;20(5):813821. (ISSN 14243903). doi:10.1016/j.pan.2020. 03. 016. Go to original source...
    25. Hart PA, Bellin MD, Andersen DK, et al. Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer. Lancet Gastroenterol Hepatol [Internet]. 2016;1(3):226237. (ISSN 24681253). doi:10.1016/S24681253(16)301066. Go to original source...
    26. Bao J, Liu D, Sun J, et al. Pancreatic cancerassociated diabetes mellitus is characterized by reduced βcell secretory capacity, rather than insulin resistance. Diabetes Res Clin Pract [Internet]. 2022;185:109223. (ISSN 01688227). doi:10.1016/j.diabres.2022.109223. Go to original source... Go to PubMed...
    27. Andersen DK, Korc M, Petersen GM, et al. Diabetes, pancreatogenic diabetes, and pancreatic cancer. Diabetes [Internet]. 2017;66(5):11031110. (ISSN 00121797). doi:10.2337/db161477. Go to original source...
    28. Bures J, Kohoutová D, Skrha J, et al. Diabetes mellitus in pancreatic cancer: a distinct approach to older subjects with newonset diabetes mellitus. Cancers [Internet]. 2023;15(14):3669. (ISSN 20726694). doi:10.3390/cancers15143669. Go to original source... Go to PubMed...
    29. Munigala S, Singh A, Gelrud A. Predictors for pancreatic cancer diagnosis following newonset diabetes mellitus. Clin Transl Gastroenterol [Internet]. 2015;6(10):e118. (ISSN 2155384X). doi:10.1038/ctg.2015.44. Go to original source... Go to PubMed...
    30. Nicholson BD, Aveyard P, Hamilton W. When should unexpected weight loss warrant further investigation to exclude cancer? BMJ [Internet]. 2019;316:15271 (ISSN 09598138). doi:10.1136/bmj.l5271. Go to original source... Go to PubMed...
    31. Yu SY, Luan Y, Dong R, et al. Adipose tissue wasting as a determinant of pancreatic cancerrelated cachexia. Cancers [Internet]. 2022;14(19):4754. (ISSN 20726694). doi:10.3390/cancers14194754. Go to original source... Go to PubMed...
    32. Wolrab D, Jirásko R, Cífková E, et al. Lipidomic profiling of human serum enables detection of pancreatic cancer. Nat Commun [Internet]. 2022;13(1):124. (ISSN 20411723). doi:10.1038/s41467021277659. Go to original source...
    33. Sharma A, Kandlakunta H, Nagpal S J S, et al. Model to determine risk of pancreatic cancer in patients with newonset diabetes. Gastroenterology [Internet]. 2018;155(3):730739.e3. (ISSN 00165085). doi:10.1053/j.gastro.2018. 05. 023. Go to original source...
    34. Michl P, Pauls S, Gress TM. Evidencebased diagnosis and staging of pancreatic cancer. Best Pract Res Clin Gastroenterol [Internet]. 2006;20(2):227251. (ISSN 15216918). doi:10.1016/j.bpg.2005. 10. 005. Go to original source...
    35. Mellenthin C, Meier CR, Jick SS, et al. Performance of the EndPAC risk score for pancreatic cancer in new onset diabetes patients with missing data - a database study in the British population. Pancreatology [Internet]. 2025;15:S1424-3903. (ISSN 14243903). doi:10.1016/j.pan.2025. 09. 017. Go to original source...
    36. Kunovský L, Dítě P, Jabandziev P, et al. Causes of exocrine pancreatic insufficiency other than chronic pancreatitis. J Clin Med. 2021;10(24):5779. doi:10.3390/jcm10245779. Go to original source... Go to PubMed...
    37. de la Iglesia D, Avci B, Kiriukova M, et al. Pancreatic exocrine insufficiency and pancreatic enzyme replacement therapy in patients with advanced pancreatic cancer: a systematic review and metaanalysis. United European Gastroenterol J [Internet]. 2020;8(9):11151125. (ISSN 20506406). doi:10.1177/2050640620938987. Go to original source... Go to PubMed...
    38. Mačáková D, Krystyník O, Cibičková Ľ. News in insulin treatment. Vnitřní lékařství [Internet]. 2024;70(1):4954. (ISSN 0042773X). doi:10.36290/vnl.2024.009. Go to original source...
    39. Li D, Yeung SC J, Hassan MM, et al. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology [Internet]. 2009;137(2):482488. (ISSN 00165085). doi:10.1053/j.gastro.2009. 04. 013. Go to original source...
    40. Mohammed I, Hollenberg MD, Ding H. A critical review of the evidence that metformin is a putative antiaging drug that enhances healthspan and extends lifespan. Front Endocrinol [Internet]. 2021;12:718942. (ISSN 16642392). doi:10.3389/fendo.2021.718942. Go to original source... Go to PubMed...
    41. Vančura A, Bu P, Bhagwat M, et al. Metformin as an anticancer agent. Trends Pharmacol Sci [Internet]. 2018;39(10):867878. (ISSN 01656147). doi:10.1016/j.tips.2018. 07. 006. Go to original source...
    42. Gandini S, Puntoni M, HeckmanStoddard B M, et al. Metformin and cancer risk and mortality: a systematic review and metaanalysis taking into account biases and confounders. Cancer Prev Res [Internet]. 2014;7(9):867885. (ISSN 19406207). doi:10.1158/19406207.CAPR130424. Go to original source...
    43. Chen Y, Mushashi F, Son S, et al. Diabetes medications and cancer risk associations: a systematic review and metaanalysis of evidence over the past 10 years. Sci Rep. [Internet]. 2023;13(1):11844. (ISSN 20452322). doi:10.1038/s4159802338431z. Go to original source...
    44. Bowers LW, Rossi EL, O'Flanagan C H, et al. The role of the insulin/IGF system in cancer: lessons learned from clinical trials and the energy balancecancer link. Front Endocrinol [Internet]. 2015;6:77. (ISSN 16642392). Go to original source...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.